1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PaxMedica, Inc.
  6. Summary
    PXMD   US70424C1045

PAXMEDICA, INC.

(PXMD)
 SummaryNewsCompanyFinancials 
Estimated financial data (e) (USD)
Sales 2019 - - -
Net income 2019 -0,60 M - -
Net cash position 2019 0,02 M - -
P/E ratio 2019 -
Yield 2019 -
Sales 2020 - - -
Net income 2020 -7,83 M - -
Net cash position 2020 0,51 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 59,1 M 59,1 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 5
Free-Float 26,3%
More Financials
Company
PaxMedica, Inc. is an early clinical stage biopharmaceutical company. The Company is focused on the development of anti-purinergic therapies (APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Fragile X syndrome tremor-ataxia (FXTAS). Its pipeline includes PAX-101 and PAX-102. It is focused on the development and testing of its lead program, PAX-101, an intravenous... 
More about the company
All news about PAXMEDICA, INC.
04/25PaxMedica, Inc. announced a financing transaction
CI
01/07PaxMedica, Inc. Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVI..
CI
01/04PaxMedica, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
2021Paxmedica, Inc. Presents Clinical Data and New Analyses from A Phase 2 Trial of Pax-101..
CI
2021PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2021PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Chil..
CI
2020PaxMedica, Inc. announced that it has received $3 million in funding
CI
2020PaxMedica, Inc. announced that it expects to receive $3 million in funding
CI
2020PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million.
CI
More news
News in other languages on PAXMEDICA, INC.
01/07PaxMedica, Inc. prévoit de lancer une étude de phase 1B sur le PAX-101 chez les patient..
01/04PaxMedica, Inc. annonce ses résultats pour les neuf mois terminés le 30 septembre 2021
More news
Income Statement Evolution
Managers and Directors
Joseph Lucchese Chief Financial Officer
Zachary Rome Chief Operating Officer & Director
Karen T. Dawes Independent Director
Paul Kevin Wotton Independent Director
Robert F. Apple Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PAXMEDICA, INC.0.00%59
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153